Video

Additional Key Data Updates from ASH 2022 on Treatment of LBCL

Author(s):

Manali Kamdar, MD,Matthew A. Lunning, DO, FACP

Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.

Related Videos
Andrew Ip, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Dasom (Caroline) Lee, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Minoo Battiwalla, MD, MS
David C. Fisher, MD
Alex Herrera, MD
Grzegorz S. Nowakowski, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Amitkumar Mehta, MD
Related Content
Smoldering Myeloma
December 11th 2024

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Ide-cel in multiple myeloma
December 10th 2024

Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Mantle Cell Lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 10th 2024

Brexu-Cel Provides Durable Responses in Relapsed/Refractory, BTK-Naive MCL

Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL
December 10th 2024

Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL